On this page
Monjuvi
tafasitamab-cxix
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Monjuvi
Proper name
tafasitamab-cxix
Licence type
351(a)
BLA number
761163
Applicant
Incyte Corporation
Center
CDER
Presentations
1
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 200MG | For Injection | Intravenous | Single-Dose Vial | Rx | July 31, 2020 |
Exclusivity
Source: Purple Book| Kind | Expires |
|---|---|
| Orphan exclusivity | July 31, 2027 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |